Abstract
Objective-To determine whether inhaled salmeterol, a new long acting inhaled 1i adrenergic agonist, reduces nocturnal bronchoconstriction and improves sleep quality in patients with nocturnal asthma.
Design-Randomised, double blind, placebo controlled crossover study.
Setting-Hospital outpatient clinics in Edinburgh. Subjects-Twenty clinically stable patients (13 women , seven men) with nocturnal asthma, median age 39 (range years.
Interventions-Salmeterol 50 [sg and 100Rg and placebo taken each morning and evening by metered dose inhaler. Rescue salbutamol inhalers were provided throughout the run in and study periods.
Main outcome measures-Improvement in nocturnal asthma as measured by peak expiratory flow rates and change in sleep quality as measured by electroencephalography.
Results-Salmeterol improved the lowest overnight peak flow rate at both 50 g (difference in median values (95% confidence interval for difference in medians) 69 (18 to 88) I/min) and 100 [tg (72 (23 to 61) I/min) doses twice daily. While taking salmeterol 50 [ig twice daily patients had an objective improvement in sleep quality, spending less time awake or in light sleep (-9 (-4 to -44) min) and more time in
Introduction
Three quarters of all asthmatic patients are woken from time to time by coughing, wheezing, and breathlessness.' 2 This nocturnal asthma is associated with significant sleep disturbance and increased nocturnal awakenings,`~and often these symptoms form the patient's main complaint. Hitherto no treatment has been shown to improve sleep quality in patients with nocturnal asthma.
Treatment of nocturnal bronchoconstriction has been limited by the short duration of action of conventional inhaled bronchodilators so that the bedtime dose does not produce effective bronchodilatation at the end of the night, when bronchoconstriction is usually at its most severe.6 Many asthmatic patients cannot tolerate therapeutically effective doses of sustained release oral 13 agonists78 or theophylline9 which, although effective in reducing nocturnal bronchoconstriction in patients with asthma,7"' do not produce any objective improvement in their sleep quality.'2 13 Salmeterol, a new inhaled 13 agonist, differs from conventional K agonists in that it produces effective bronchodilatation for 12 hours after a single inhaled dose. 14 The object of the our study was to evaluate both subjectively and objectively the effect of inhaled salmeterol on nocturnal bronchoconstriction and sleep quality in patients with nocturnal asthma.
Methods
Twenty patients with nocturnal asthma were entered into a randomised, double blind, crossover study (mean age 39 (range 18-60) years; seven men) to BMJ VOLUME 301compare three inhaled treatments: 50 tg and 100 [ig inhaled salmeterol aerosol twice daily and placebo aerosol twice daily. Nocturnal asthma was defined as an average overnight fall in peak expiratory flow rate of at least 15% in association with at least two nocturnal awakenings a week due to wheezing, coughing, or breathlessness over a two week run in period in a patient with known asthma. The mean percentage predicted peak expiratory flow rate of the patients during the run in period was 63% (SD 16%). All 132 agonists were withdrawn during the study, apart from the study doses and a rescue salbutamol metered dose inhaler that was provided. All Only data from the second night on each occasion were analysed, the first night serving for acclimatisation. Each patient spent the same time in bed on all three study limbs (median 402 min).
The significance of observed changes was assessed by Wilcoxon signed ranks testing with application of the Bonferroni correction for multiple comparisons.
Results

TOXICITY
One patient was withdrawn on day 1 because of palpitation caused by sinus tachycardia while taking salmeterol 100 Fg twice daily. Another patient withdrew from the study for social reasons. One patient who required maintenance oral prednisolone (5 mg per day) died in status asthmaticus in another hospital after inhaling a perfume while taking salmeterol 100 [tg twice daily. His salmeterol had been stopped on admission to hospital, seven hours before death. He had not received a booster dose of oral or intravenous steroid on admission. No patients reported any other side effects from taking salmeterol in either dose, despite being specifically asked about possible side effects at the end of each limb of the study.
DATA ANALYSIS
Data from 17 patients who completed all three limbs of the study and data from the first two limbs of the study in the case of the patient who died during the third limb of the study were used for analysis. Both doses of salmeterol produced significant improvements in morning and daytime asthma symptoms with fewer night time awakenings from asthma ( Although salmeterol 100 tg twice daily was as effective a bronchodilator as salmeterol 50 tg in our study, it did not improve sleep quality whereas the lower dose did. We think that this is unlikely to be a chance finding as these results were consistent through several different sleep variables tested in each group. It seems likely that the higher dose of salmeterol may have caused some degree of central nervous system stimulation, which offset the potential benefit derived from its bronchodilator action. The lipophilic side chain of the compound may allow it to cross the blood-brain barrier; however, quantitative whole body autoradiography in rats suggests that only a small proportion of a salmeterol dose crosses this barrier (I Skidmore, personal communication).
Although salmeterol improved peak expiratory flow measurements; reduced asthma symptoms on waking and during the day; reduced the 24 On physical examination at presentation the patient was pale and mildly jaundiced with prognathism and prominent maxillary bones. His anterior abdominal wall showed numerous scarification marks. There was hepatosplenomegaly. The spine showed prominent gibbous at L3 level, with a slight tilt to the right. At this level there was a non-tender bony mass of 5 cm x 3 cm in the midline. The overlying skin showed three healed pressure ulcers, the right leg was weak (power 4/5), and his gait indicated slight scoliosis to the right and a slight limp of the right foot. The result of the straight leg raising test was positive for the right leg at 600. The right hamstring muscles were tender to palpation. Sensation to touch and pain was intact. There was a left lateral malleolar ulcer, which was healing with paper thin re-epithelialisation.
Laboratory investigations disclosed anaemia (haemoglobin 87 g/l), an erythrocyte sedimentation rate of 113 mm in the first hour, genotype SS, and a Mantoux test result of 10 mm. Results of liver function tests and serum electrolyte, urea, and creatinine concentrations were normal. Chest and skull radiographs were normal except for coarse trabeculation of the ribs. Plain abdominal radiographs showed multiple faceted gall stones. Spinal radiographs showed diffusely generalised osteoporosis, trabeculation, and pencil
